Tatsi Christina, Saidkhodjaeva Lola, Flippo Chelsi, Stratakis Constantine A
Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland, 20892, USA.
J Endocr Soc. 2022 May 17;6(7):bvac080. doi: 10.1210/jendso/bvac080. eCollection 2022 Jul 1.
Subclinical pituitary hemorrhage, necrosis, and/or cystic degeneration (SPH) presents mainly in large tumors and prolactinomas. The characteristics of patients with Cushing disease (CD) and SPH are not known.
To determine if SPH affects the presentation and biochemical profile of young patients with CD.
Pediatric and adolescent patients who were diagnosed with CD between 2005 and 2021 and available magnetic resonance imaging images were evaluated for SPH. The clinical and biochemical characteristics of patients with and without SPH were compared.
Evidence of possible SPH was present in 12 out of 170 imaging studies (7.1%). Patients with and without SPH had similar age at diagnosis and sex distribution but differed in disease duration (median duration: 1.0 year [1.0-2.0] in the SPH group vs 2.5 years [1.5-3.0] in the non-SPH group, = .014). When comparing their biochemical evaluation, patients with SPH had higher levels of morning adrenocorticotropin (ACTH) (60.8 pg/mL [43.5-80.3]) compared to patients without SPH (39.4 pg/mL [28.2-53.2], = .016) and the degree of cortisol reduction after overnight high dose (8 mg or weight-based equivalent) dexamethasone was lower (-58.0% [-85.4 to -49.7]) compared to patients without SPH (85.8 [-90.5 to -76.8], = .035). The presence of SPH did not affect the odds of remission after surgery or the risk of recurrence after initial remission.
SPH in ACTH-secreting pituitary adenomas may affect their biochemical response during endocrine evaluations. They may, for example, fail to suppress to dexamethasone which can complicate diagnosis. Thus, SPH should be mentioned on imaging and taken into consideration in the work up of pediatric patients with CD.
亚临床垂体出血、坏死和/或囊性变(SPH)主要见于大腺瘤和催乳素瘤。库欣病(CD)患者和SPH患者的特征尚不清楚。
确定SPH是否会影响年轻CD患者的临床表现和生化特征。
对2005年至2021年间诊断为CD且有可用磁共振成像图像的儿科和青少年患者进行SPH评估。比较有和没有SPH的患者的临床和生化特征。
170项影像学研究中有12项(7.1%)存在可能的SPH证据。有和没有SPH的患者在诊断时的年龄和性别分布相似,但病程不同(SPH组中位病程:1.0年[1.0 - 2.0],非SPH组为2.5年[1.5 - 3.0],P = 0.014)。在比较生化评估时,与没有SPH的患者(39.4 pg/mL[28.2 - 53.2],P = 0.016)相比,有SPH的患者早晨促肾上腺皮质激素(ACTH)水平更高(60.8 pg/mL[43.5 - 80.3]),过夜高剂量(8 mg或基于体重的等效剂量)地塞米松后皮质醇降低程度更低(-58.0%[-85.4至-49.7]),而没有SPH的患者为85.8[-90.5至-76.8],P = 0.035)。SPH的存在不影响手术后缓解的几率或初始缓解后复发的风险。
分泌ACTH的垂体腺瘤中的SPH可能会影响其在内分泌评估期间的生化反应。例如,它们可能对地塞米松无反应,这会使诊断复杂化。因此,应在影像学检查中提及SPH,并在儿科CD患者的检查中予以考虑。